TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Cmax of BAY2327949
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of BAY2327949
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax,u of BAY2327949
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCu of BAY2327949
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin thermometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Hygrometry under costume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantitative sensory testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Participants Achieving Pain Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concordance of biomarker kinetics with disease evolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tobacco quit rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maternal estimated blood loss (EBL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Lens opacities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Daily opioid dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported opioid use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: AUC ΔH2 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Train-of-four (TOF) Ratio <0.9 at PACU Arrival
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: success rate defined as absence of radiological degenerative disease at adjacent levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number and Percentage of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Flexor tendon excursion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Monitoring of hyperlipidemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Monitoring of blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Acceptability of Springfusor
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants Who Were Intubated
Endpoint domain: Adverse events/effects
Primary endpoint: Duration of Intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: cord blood IgE levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Neutralizing antibody titers to DENV-1, DENV-2, DENV-3, and DENV-4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Induction of seropositivity after second dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Emax - Maximum Drug Liking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Relative Change in the Percentage of Liver Fat Mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: High Contrast Distance Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: High Contrast Intermediate Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: High Contrast Near Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: migraine quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Help seeking behavior
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Credibility as measured by the Treatment Credibility Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Perceived stress as measured by the Perceived stress scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Identification of sentinel lymph node(s)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Youth Urine Drug Screens
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Youth Substance Use Frequency and Problems
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in depth of artificial lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in area of artificial lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: AUCtau of Narlaprevir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCtau of Tenofovir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Raltegravir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCtau of Raltegravir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anthropometric body composition profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in brain volume with blood brain barrier dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in serum biomarkers of blood brain barrier dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Glasgow Outcome Scale-Extended (GOS-E)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Rivermead Post Concussion Symptom Questionnaire (RPSQ)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in Patient-Reported Outcomes Measurement Information System (PROMIS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in post-traumatic epilepsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Internalizing symptoms in children
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Externalizing symptoms in children
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in fat concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in refractive spherical equivalent
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EVA pain scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Venous thromboembolic risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Neutrophil response to exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Area under the curve for insulin from 0-8 hours (AUCins0-8h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum concentration of insulin (CMaxIns)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area under the curve for glucose infusion rate from 0-12 hours (AUGgir0-12h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Materno-fetal complications
Endpoint domain: Adverse events/effects
Primary endpoint: Time-Weighted Sum of Pain Intensity Difference Score From Baseline to 6 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time-Weighted Sum of Pain Intensity Difference Score From Baseline to 12 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with laboratory abnormalities by grade
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with a dose-limiting toxicity (DLT) at each dose level
Endpoint domain: Adverse events/effects
Primary endpoint: Cancer risk assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Growth hormone exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health Assessment Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Balance error scoring system (BESS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activities-specific Balance Confidence (ABC)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Lower limb muscle power during a stair climb test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower limb muscle power during a sit-to-stand test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bleeding continuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Size of arsenical keratotic nodules
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Duration of Invasive Mechanical Ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in severity of Atopic Dermatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of cases with significant bacteriuria and urinary symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Household Food Security Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child and caretaker dietary intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Chimerism levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality status at end of project
Endpoint domain: Mortality/survival
Primary endpoint: Apnea / hypopnea events index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cognitive Efficacy
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in global neurocognitive function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: HBsAG Prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of Participants Achieving Complete Renal Response (CRR) at Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change From Baseline in FEV1 AUC0-6 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Participants Who Made at Least One Critical Error
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: AUC(0-infinite) for bioavailability assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of PK parameters for single oral dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of PK parameters for dose proportionality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of lacrimal duct obstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Inflammatory markers in the amniotic fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time Above Threshold-Absolute Neutrophil Count (TAT-ANC) of ≥ 500 Cells/Microliter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Pain Self-Efficacy Questionnaire (PSEQ) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of patients with successful conservative treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: occurrence of surgical site infections
Endpoint domain: Adverse events/effects
Primary endpoint: Duration of action to reduce vaginal pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean concentration of plasma AB peptides
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma levels of Tau protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of GSK163090
Endpoint domain: Adverse events/effects
Primary endpoint: 28-Day All-cause mortality
Endpoint domain: Mortality/survival
Primary endpoint: Change in CD8+ Positive Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in CD4+ Positive Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Response Rate in Treatment of Nasolabial Fold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success on the Premature Ejaculation Bothersome Evaluation Questionnaire PEBEQ Item 3
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Target vessel occlusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Percentage of Participants Showing Clinical Benefit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Confirmed Herpes-Zoster
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With One or More Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Measurement of margin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Primary patency of the target lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score on personality scales
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Score on interpersonal scales
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Score on eating disorder scales
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score on symptom scales
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of adverse reactions to CM during ERCP
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Glucagon-induced endogenous glucose production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: NIHSS differential
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Detection of circulating tumor cells (CTC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: ADL independence change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Walking performance change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health-related well-being perception
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of grade 3 or greater toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Changes of EGFR expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence Rate of All ADRs
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence Rate of All SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Allergic Rhinitis Symptom Severity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Neck and shoulder pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of episodes of acute rejection after LTx
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Protein nutritional assessment index or nutritional status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sum of Pain Intensity Difference using a 100mm Visual Analog Scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biomarker Response of CD3 and CD68
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sensitivity in detecting early lung cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in kinematics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Choice data
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Fatty acid ratio in cord blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADHD at 4 years old
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: ADHD at 7 years old
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in worst daily pain assessed with the visual analogue scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in motor cortex blood flow assessed by near infrared spectroscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Functional Pain Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pediatric Evaluation of Disability Inventory-Computer Adaptive Test (PEDI-CAT) Daily Living
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Assessment of Motor and Process Skills (AMPS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: rate of vesicoureteral reflux (VUR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: incidence of anastomotic stricture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: post operative changes in the mean serum creatinine level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of RO7017773
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Taste Assessment, as Measured by Taste Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Fasting and postprandial gastric volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of Participants With Confirmed Objective Response (OR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes in visual acuity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement ratio of Fugl-Meyer assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Developed Factor VIII (FVIII) Inhibitors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Identification of propulsion cycles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Classification of propulsion cycles by effort intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease diabetes related distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Increase in Clinical Attachment Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient responses (CR, PR, MR, overall response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PES/WES scores of single implant crowns
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OHIP questionnaire patient reported outcome
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Identification of metabolomic markers for relapse risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Component Alignment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of eyes with postoperative complications
Endpoint domain: Adverse events/effects
Primary endpoint: Gamma camera-based whole-body 99mTc-HE3-G3 uptake value (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SPECT-based 99mTc-HE3-G3 uptake value in tumor lesions (counts)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: progression-free survival at 3 months
Endpoint domain: Mortality/survival
Primary endpoint: Percent Change From Baseline in Femoral Neck Bone Mineral Density (BMD) at Month 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Experiencing One or More Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of misplacement of the tip of CVC
Endpoint domain: Adverse events/effects
Primary endpoint: Change in molecular signature
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in immunological signature
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in HAI antibody titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Physiological assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of Violence Against Women
Endpoint domain: Adverse events/effects
Primary endpoint: Women's Experience with Battering
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Safety Behavior Checklist
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Decisional Conflict Scale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Lung Volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes